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 ABSTRACT 
Paricalcitol, 19-nor-1, 25-dihydroxvitamin D2, is a novel 1,25–dihydroxyvitamin D2 analogue, which has greater potential to suppress 
parathyroid hormone without inducing significant hypercalcemia and hyperphosphatemia.  We therefore investigated its role in treatment of 
patients with moderate to severe secondary hyperparathyroidism (SHPT) who were refractory to conventional therapy with Calcitriol and 
Cinacalcet HCl.  Eight patients were recruited in whom conventional therapy was stable over the past 3 months.  After a washout period of 2 
weeks, calcijex injections were replaced by Paricalcitol.  Paricalcitol induced more suppression of iPTH compared to the conventional therapy 
without significant hypercalcemia, hyperphosphatemia or side effects.  The conversion ratio was approximately 1:2.5 (calcitriol:paricalcitol).  In 
conclusion, injectable Paricalcitol is superior to Calcitriol in treatment of SHPT. 
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INTRODUCTION 
Disturbances in mineral and bone metabolism are common 
in patients with chronic kidney disease [1].  They include; 
hyperphosphatemia due to decrease excretion through the 
failing kidney, hypocalcemia due to decline in the gut 
absorption due to decline in the conversion of 25 
hydroxyvitamin D to its potent 1,25 dihydroxy version and 
lastly the activation of parathyroid gland in its attempt to 
correct hyperphosphatemia.  The parathyroid gland is also 
affected by the declining levels of serum calcium and vitamin 
D in addition to altered set-point of serum calcium leading to 
more hyperplasia, secretion and further damage [2].  With 
the declining kidney function mineral abnormalities produce 
osteomalacia (decreased bone calcification) and/or 
secondary hyperparathyroidism (osteitis fibrosa cystica) 
with increased risk of fractures, bone deformities, bone 
cysts, osteopenia, resistance to erythropoietin, intractable 
purities, spontaneous tendon rupture, periarthritis, 
myopathy, growth failure in children and extraskeletal 
calcification  [3].  Moreover, secondary hyperparathyroidism 
has been recognized as a uremic toxin via increasing the 
intracellular calcium, resulting in disturbances in the 
function of virtually every organ system [4].  Unfortunately, 
treatment of moderate cases of SHPT with calcium-
containing phosphate binders and the available vitamin D 
analogues viz. One alpha (1 hydroxyvit D) and Calcitriol 
(1,25 dihydroxyvit D), though useful and equivalent [5], has 
been associated with hypercalcemia [6].  Furthermore, 
hyperphosphatemia was noted to be more difficult to control 
with Calcitriol and one alpha due to enhanced gut absorption 
and release through enhanced bone resorption [7].  Such 
hypercalcemia with or without high CaXP product has been 
recently recognized as a risk factor for visceral and vascular 
calcification which was linked to increased morbidity in 
dialysis patients [8].  Cinacalcet HCl (Mimpara) has been 
introduced recently into the field and had an impressive 
suppression of the parathyroid gland [9].  However, its 
gastrointestinal side effects limited its use.  Paricalcitol, 19-
nor-1,25-dihydroxvitamin D2, is a new analogue of 
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ergocalciferol which appears to have the same suppressive 
effect on SHPT, but with less direct effect on the gut and 
bone.  Crossover studies evaluating its efficacy over the 
treatment with the conventional therapy of IV Calcitriol 
(Calcijex) and Mimpara are essential to overcome the 
interpatient variability in response to such therapy.  This 
pilot study was conducted to answer the latter questions. 
PATIENTS AND METHODS: 
This prospective open-label crossover study was performed 
at Edeliah dialysis center which is responsible for the care of 
nearly 360 patients residing in the capital area of Kuwait.  
All patients are receiving maintenance hemodialysis three 
times weekly with a dialysate calcium concentration of 2.5 
mmol/L.  All patients are receiving regularly nutritional 
counseling that limits their phosphorus intake to 1 g/day 
and calcium to 2 g/day.  Calcium supplementation 
with/without non-calcium containing phosphate binders 
sevelemer (Renvella; Genozyme Corp, Cambridge, MA) are 
given to lower phophorus level to acceptable range (< 1.78 
mmol/L) and keep calcium levels at the upper limit of 
normal (2.37 mmol/L) yet avoiding CaXP product above 
4.22.   
Selection criteria: 
Patients with persistent moderate to severe SHPT (iPTH > 
30 pmol/L) for at least 3 months despite treatment with 
calcijex and cinacalcet were identified.  However, only those 
who were stable medically, socially and psychologically 
were selected to ensure compliance with diet and 
medications.    
Exclusion criteria: 
Patients were excluded from the study if they had history of 
allergic reaction to calcitriol or other vitamin D analogues, a 
current malignancy, clinically significant liver disease, a 
history of drug or alcohol abuse within the last 6 months, or 
evidence of blood-born infections such as hepatitis or HIV.  
None of the patients recruited had enlarged parathyroid 
gland on ultrasonography or positive activity on parathyroid 
subtraction nuclear scan.   
Crossover to paricalcitol: 
Calcitriol was discontinued for 2 weeks prior to starting 
paricalcitol.  Paricalcitol therapy was initiated by converting 
patients from Calcitriol therapy to Paricalcitol at a starting 
dose of 2.5-5 ug after each dialysis session.  Further 
adjustment in calcium and phosphate supplementation as 
well as Paricalcitol and Cinacalcet doses, were determined at 
the discretion of the treating physician to achieve better 
suppression of parathyroid hormone level.  Patients were 
followed up for 3 months in both stages with a 2 weeks 
period of wash out.  For the sack of the study, corrected 
serum calcium, phosphorus, alkaline phosphates were 
measured every 2 weeks.  Parathyroid hormone was 
measured by means of an intact hormone 
radioimmunoassay. 
RESULTS 
Initially, 10 patients were included on the study and were 
observed for 3 months on the conventional therapy.  
However, by the end of the first phase, 2 had to be excluded 
for non-compliance with their oral medications.  
Demographical data and the ancillary therapy received 
during the 2 phases of treatment are included in Table.1.   
Changes in corrected calcium, phosphorus, alkaline 
phosphatase and iPTH during the 2 phases of the study are 
presented in Table.2.  As shown in Table.2, 7 patients had 
inadequate response to the conventional therapy with 
Calcitriol and Cinacalcet with iPTH levels above 33 pmol/L 
and one patient could not tolerate Calcitriol due to 
hypercalcemia.   
Starting point: 
Levels of iPTH and alkaline phosphatase increased at the end 
of washout period. 
Paricalcitol phase of treatment: 
All patients experienced more suppression of iPTH and had 
reached the target iPTH (< 33 pmol/L).   
Interpatient variation of response: 
Assessment of individual patients showed the following: 
1- Patient 1 showed adequate response at a conversion 
ratio of 1:2.5. 
2- Patient 2 showed favorable response yet the dose of 
Paricalcitol had to be increased up to 5 ug 3 per week 
i.e. a conversion ratio of 1:5. 
3- Patient 3 was on 60 mg daily of Cinacalcet and his 
serum calcium was 2.41 mmol/L, low phosphorus 
(0.72 mmol/L) and low CaXP product despite absence 
of P-binders.  Interestingly, Paricalcitol treatment was 
not associated with worsening of hypercalcemia yet 
serum P improved to normal with improvement of his 
SHPT. 
4- Patient 4 required 5ug thrice weekly of Paricalcitol in 
the first 2 months yet the final maintenance dose was 
in accordance with a 1:2.5 conversion ratio. 
5- Patient 5 who already could not tolerate vitamin D 
analogue due to hypercalcemia, tolerated Paricalcitol 
without significant drop in his iPTH. 
6- Patient 6 & 7 had low calcium levels during the second 
month that responded to temporary discontinuation of 
cinacalcet.  By that, iPTH level had dropped from 86 to 
64 pmol/L in the first patient and 72 to 46 in the 
second.  Reintroduction of Cinacalcet in the last month 
at a lower dose (30 mg every other day resulted in 
further decline in iPTH to the target level without 
hypocalcemia.  
7- Patient 8 had high P and serum calcium at the upper 
limit of normal.  The initial conversion ratio for 
Calcitriol to Paricalcitol was 2:2.5.  However, at later 
weeks paricalcitol dose had to be increased to 5 ug 
without further worsening of hypercalcemia or 
hyperphosphatemia to achieve the target iPTH level.  
Safety and adverse side effects: 
1- Paricalcitrol therapy was not associated with 
significant hypercalcemia, hyperphosphatemia or high 
CaXP product. 
2- None of the patients treated with Paricalcitol had 
experience significant allergic reaction to the IV 
medication, cardiovascular instability or GI side effects. 
DISCUSSION 
The safety of and efficacy of Paricalcitol in treatment of 
SHPT with less hypercalcemia and hyperphosphatemic side 
effect have been established for many years [10].  Moreover, 
an animal study has shown that the drug did not increase 
aortic calcium content in animals compared to Calcitriol 
[11].  In fact, the meeting of the WHO International Working 
Group for Drug Statistics Methodology in 24th March 2009 
reclassified Paricalcitol from being simply another vitamin D 
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analogue to a an anti-parathyroid drug and has been given 
the new code (H05BX02).   Comparative studies against 
Calcitriol have shown that the use of Paricalcitol both 
improve patient’s survival [12] and health economics via 
cost-effective analysis [13].  Interestingly, cross-over studies 
comparing Calcitriol and Paricalcitol essential to overcome 
the interpatient variability of response to both drugs are 
limited to 3 only.  The first study compared the shift from 
Calcitriol treatment to Paricalcitol in 73 patients on 
maintenance hemodialysis and patients were followed for 6 
months [14] while the second recruited 59 patients for one 
year [15].  Both investigators admitted that some of their 
patients missed fewer doses of Paricalcitol.  The third and 
more recent study recruited 12 patients who were followed 
for one year [16].  In our study, we added the factor of using 
the available maximal conventional therapy not only with 
Calcitriol but with Cinacalcet.  Our study showed that iPTH 
levels were significantly reduced with amelioration of the 
previous hyperphosphatemia and hypercalcemia noted in 
the previous phase of the conventional therapy.  This 
phenomenon may have been related to the vitamin D 
receptor selectivity of the chemically produced Paricalcitol 
being only on the parathyroid gland compared to the 
naturally produced Calcitriol.  The latter effect may be 
desirable for normal people and renal patients with 
osteomalacia and hypocalcemia but not for patients with 
already advanced stage of SHPT.  Moreover, such an effect is 
shown in our study to be an additive one to the calcimimetic 
effect of Cinacalcet since it acts differently via improving the 
calcium-sensing receptors located on the surface of the chief 
cells of the parathyroid gland [17].  In our study, the dose 
conversion ratio from Calcitriol to paricalcitol is nearly 1:2.5 
rather than 1:3 reported earlier [14-16].  This issue is 
practically useful since the ampoule of Calcitriol contains 
either 1 or 2 ug while that of Paricalcitol is 5 ug/ml.  
REFERENCES: 
1- Feinfeld DA, Sherwood LM.  Parathyroid hormone and 1,25 
(OH)2D3 in chronic renal failure.  Kidney Int 1988; 33:1049-
1058. 
2- Brown EM, Wilson RE, Eastman R.  Abnormal regulation of 
parathyroid hormone release by calcium in secondary 
hyperthyroidism due to chronic renal failure.  J Clin 
Endocrinol Metab 1982; 54:172-179.  
3- Liach F.  Secondary hyperparathyroidism in renal failure: the 
trade-off hypothesis revisited.  Am J Kidney Dis 1995; 25: 663-
679. 
4- Massry, SG, Smogorzewski, M. Mechanisms through which 
parathyroid hormone mediates its deleterious effects on 
organ function in uremia. Semin Nephrol 1994; 14:219-231.   
5- El-Reshaid K, El-Reshaid W, Sugathan TN, Al-Muhanadi S, 
Sivanandan R.  Comparison of the efficacy of two injectable 
forms of vitamin D3 and oral one alpha in treatment of 
hyperparathyroidism in patients on maintenance 
haemodialysis.  Am J Nephrol 1997; 17:505-510. 
6- Gallieni M, Brancaccio D, Padovese P, et al.  Low-dose 
intravenous calcitriol treatment of secondary 
hyperparathyroidism in hemodialysis patients.  Italian Group 
for the study of intravenous Calcitrol.  Kidney Int 1992; 42: 
1191-1198. 
7- Hruska KA, Teitelbaum SL.  Renal osteodystrophy.  N Engl J 
Med 1995; 333:166-174. 
8- Block GA, Hulbert-Sharon TE, Levin NW, et al.  Association of 
serum phosphorus and calcium X phosphorus product with 
mortality risk in chronic hemodialysis patients: A national 
study.  Am J Kidney Dis 1998; 31:607-617.   
9- Sharon M, Glenn C, Jack C, et al.  Achieving NKF-K/DOQI TM 
bone metabolism and disease treatment goals with cinacalcet 
HCl.  Kidney Int 2005; 67:760-771. 
10- Martin KJ, Gonzalez EA, Gellens M, et al.  19-Nor-1-alpha-25-
dihydroxyvitamin D2 (Paricalcitol) safely and effectively 
reduced the levels of intact parathyroid hormone in patients 
on hemodialysis.  J Am Soc Nephrol 1998; 9:1427-1432. 
11- Mizobuchi M, Finch JL, Martin DR, Slatopolsky E.  Differential 
effects of vitamin D receptor activators on vascular 
calcification in uremic rats.  Kidney Int 2007; 1-7. 
12- Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R.  
Survival od patients undergoing hemodialysis with 
Paricalcitol or Calcitriol therapy.  N Engl J Med 2003; 349:446-
456. 
13- Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague 
SM.  Paricalcitol-treated patients experience improved 
hospitalization outcomes compared with calcitriol-treated 
patients in real-world clinical settings.  Nephrol Dial 
Transplant 2004; 19:1174-1181. 
14- Mittman N, Khanna R, Chattopadhyay J, et al.  Paricalcitol 
therapy for secondary hyperparathyroidism in patients on 
maintenance hemodialysis previously treated with calcitriol: a 
single-center crossover study.  Kidney Int 2006; 70:S64-67.   
15- Desiraju B, Mittman N, Meyer K, et al.  Treatment of secondary 
hyperparathyroidism (SHPT) with paricalcitol (P) versus 
calcitriol (C) : a two year, single center crossover comparison 
[abstract no. SA-PO1009].  American Society of Nephrology 
(ASN) 39th Renal Week Meeting; 2006 November 14-19; San 
Diego (CA).  
16- Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.  
Beneficial effects of better control of secondary 
hyperparathyroidism with paricalcitol in chronic dialysis 
patients.  J Nephrol 2009; 22:59-68. 
17- Brancaccio D, Bommer J, Coyne D.  Vitamin D receptor 
activator selectivity in the treatment of secondary 
hyperparathyroidism: understanding the differences among 
therapies.  Drugs 2007; 67:1981-1998. 
El-Reshaid et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2020; 10(3):148-151 
ISSN: 2250-1177                                                                                  [151]                                                                                 CODEN (USA): JDDTAO 
Table.1 Demographic data and therapy before and after conversion of injectable calcitriol (calcijex) to paricalcitol (zemplar) 
Patient age Sex TRD Durtion on Phases of     
Ancillary 
treatment       
number (years)     HD (years) treatment Calt-0 Calat-3 Renv-0 Renv-3 Mimp-0 Mimp-3 
1 57 M Diabetic 4.5 Calcijex 1gX3 1gX3 800mgX2 800mgX2 30mg/d 30mg/d 
     
Zemplar 1gX3 1gX3 800mgX3 800mgX2 30mg/d 30mg/d 
2 46 M Chronic GN 2.5 Calcijex 1gX3 1gX3 No No 30mg/d 30mg/d 
     
Zemplar 1gX3 1gX3 No No 30mg/d 30mg/d 
3 79 F Nephroangiosclerosis 7 Calcijex 1gX3 1gX3 No No 60mg/d 60mg/d 
     
Zemplar 1gX3 1gX3 No No 60mg/d 60mg/d 
4 61 F Nephroangiosclerosis 3 Calcijex 1gX3 1gX3 800mgX3 800mgX3 30mg/d 30mg/d 
     
Zemplar 1gX3 1gX3 800mgX3 800mgX2 30mg/d 30mg/d 
5 66 F Diabetic 5 Calcijex No No 800mgX3 800mgX3 30mg/d 30mg/d 
     
Zemplar No No 800mgX3 800mgX3 30mg/d 30mg/d 
6 70 M Chronic GN 3 Calcijex 1 gX2 1 gX2 800mgX3 800mgX3 30mg/d 30mg/d 
     
Zemplar 1 gX3 1 gX3 800mgX3 No 30mg/d 15mg/d 
7 73 F 
Chronic 
tubulointerstitial 13 Calcijex No No 800mgX3 800mgX3 30mg/d 30mg/d 
     
Zemplar 1gX3 1gX3 800mgX3 800mgX3 30mg/d 15mg/d 
8 25 F Chronic GN 2.5 Calcijex 1gX2 1gX2 800mgX3 800mgX3 60mg/d 60mg/d 
     
Zemplar 1gX3 1gX3 800mgX3 800mgX3 60mg/d 60mg/d 
                   
 
